U.S. Molecular Diagnostics Market Size To Hit USD 9.78 Bn By 2032

The U.S. molecular diagnostics market size was exhibited at USD 6.1 billion in 2022 and it is expected to hit around USD 9.78 billion by 2032, growing at a CAGR of 4.83% during the forecast period from 2023 to 2032.

Download Free Sample Copy for Better Understanding@ https://www.novaoneadvisor.com/report/sample/8383

Key Takeaways:

• The respiratory disease segment led the market with a share of 40.83% in 2022.
• The healthcare-associated infections segment is expected to witness the fastest growth from 2023 to 2032.
• The hospital core laboratory contributed the largest share of 38.49% in 2022.
• Reference labs is expected to expand at the fastest CAGR during the forecast period.

The increasing prevalence of infections and technological advancements in molecular diagnostic tests drive the market. Furthermore, the presence of favorable reimbursement policies coupled with rising government support in the form of funding and initiatives for the development of diagnostics tests is anticipated to drive the U.S. molecular diagnostics growth over the forecast period.

The COVID-19 pandemic has positively impacted the market by encouraging players to develop novel and rapid diagnostic kits capable of detecting coronavirus. This has resulted in positive revenue growth for major market players operating in the infectious disease segment. For instance, Thermo Fisher Scientific reported 150% revenue growth owing to the rising demand for diagnostics offerings in April 2021. However, the rising adoption of vaccination in the region is anticipated to reduce the demand for COVID-19 testing over the forecast period.

Moreover, increasing incidences of infections in the country primarily drive the demand for cost-effective and efficient diagnostics techniques. According to a study published by the Journal of Clinical Virology in March 2023, enterovirus infection incidents increased by 21.7% compared to the previous year. Furthermore, enterovirus majorly affects the population with ages less than 5 years, of which around 41% of the infected toddlers require supplemental oxygen. In addition, according to the article published by the National Library of Medicine in May 2021, around 40 % of the U.S. population in the U.S. is affected by H. pylori infection every year.

The presence of government support in the form of approvals and funding is anticipated to fuel the market growth over the forecast period. For instance, in May 2022, Abbot received approval for its Alinity m STI Assay from the U.S. FDA. The test is capable of differentiating and detecting STIs. In addition, in 2020, ASPR’s Biomedical Advanced Research and Development Authority and NIH’s National Institute of Allergy and Infectious Diseases organized the Antimicrobial Resistance Diagnostic Challenge in which Visby Medical’s rapid PCR test won USD 19 million in federal funding.

High prices associated with molecular tests are one of the major factors impeding the market for U.S. molecular diagnostics. Furthermore, the scarcity of comparable tests is another reason for price hikes. The significant variations in prices for different applications of each molecular diagnostic product further compound this problem. However, the presence of favorable reimbursement policies in the country is anticipated to fuel the market demand. For instance, in January 2022, the U.S. Department of Health and Human Services announced that individuals with group health plans or covered by private health insurance who purchase at-home COVID-19 tests will get benefits of cost coverage from the insurance or plan.

U.S. Molecular Diagnostics Market Report Scope

Procure Complete Report (250 Pages PDF with Insights, Charts, Tables, and Figures)@ https://www.novaoneadvisor.com/report/checkout/8383

Segments Insights:

Disease Insights

The respiratory disease segment dominated the market with a share of 40.83% in 2022. The growth is attributed to the increasing prevalence of respiratory infections such as HPIVs, MDR-TB, and group A streptococcal, among others, coupled with the increasing awareness regarding the availability of diagnostics tests for diagnosing and treatment of infections. According to a study conducted by the CDC, there has been a significant increase in the number of parainfluenza infections till December 2022. This is further contributing to the growing number of hospitalizations caused by HPIVs.

The healthcare-associated infections segment is anticipated to witness the fastest growth from 2023 to 2030. The growth is attributed to the increasing incidences of HAI and technological advancements in diagnostic techniques are driving the growth. According to a study published by the National Library of Medicine in December 2022, around 4% of the total hospitalizations are affected by HAI in the U.S. every year. Furthermore, rising government support in the form of initiatives to reduce the incidence of infections during hospitalizations is anticipated to fuel the growth over the forecast period. For instance, in 2022, the Centers for Medicare & Medicaid Services introduced the Hospital-Acquired Condition (HAC) Reduction Program to encourage hospitals to reduce incidences of infection during hospitalization and improve overall patient safety.

End-use Insights

The hospital core laboratory held the largest share of 38.49% of the market for U.S. molecular diagnostics in 2022 and is anticipated to grow at the fastest CAGR over the forecast period. The segment growth is attributed to the increasing prevalence of infections, such as MRSA, Staphylococcus aureus (SA), and enterovirus. According to a study published by NCBI in May 2022, the prevalence of SA carriage was found to be 30.2% among individuals aged between 18 years and 64 years, 20.7% among children, and 16.7% among people aged more than 65 years.

Reference labs are also expected to register a considerable CAGR during the forecast period. Increasing government support through initiatives and reimbursement policies is anticipated to drive market growth over the forecast period. For instance, in March 2023, the U.S. government launched the AHRQ Safety Program for MRSA Prevention. The program is anticipated to boost the demand for molecular diagnostic techniques by creating awareness regarding multidrug-resistant organisms and MRSA transmission.

Related Reports

• In Vitro Diagnostics Market : The global In Vitro Diagnostics market size was exhibited at USD 133.19 billion in 2022 and is projected to hit around USD 210.83 billion by 2032, growing at a CAGR of 4.7% during the forecast period 2023 to 2032.
• Infectious Disease Molecular Diagnostics Market: The global Infectious Disease Molecular Diagnostics Market market size was exhibited at USD 34.94 billion in 2022 and is projected to hit around USD 47.41 billion by 2032, growing at a CAGR of 3.1% from 2023 to 2032.
• Point of Care Molecular Diagnostics Market : The global point-of-care molecular diagnostics market size was exhibited at USD 8.19 billion in 2022 and is projected to hit around USD 11.22 billion by 2032, growing at a CAGR of 3.2% from 2023 to 2032.
• North America In Vitro Diagnostics Market : The North America in vitro diagnostics market size was exhibited at USD 50.19 billion in 2022 and is projected to hit around USD 66.86 billion by 2032, growing at a CAGR of 2.91% from 2023 to 2032.
• U.S. Infectious Respiratory Disease Diagnostics Market : The U.S. infectious respiratory disease diagnostics market size was exhibited at USD 22.90 billion in 2022 and is projected to hit around USD 34.56 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.
• U.S. Tissue Diagnostics Market : The U.S. tissue diagnostics market size was exhibited at USD 3.89 billion in 2022 and is projected to hit around USD 5.71 billion by 2032, growing at a CAGR of 3.92% from 2023 to 2032.
• In-vitro Diagnostics Enzymes Market : The global in-vitro diagnostics enzymes market size was exhibited at USD 2.26 billion in 2022 and is projected to hit around USD 5.33 billion by 2032, growing at a CAGR of 8.98% during the forecast period 2023 to 2032.
• Artificial Intelligence In Diagnostics Market: The global artificial intelligence in diagnostics market size was exhibited at USD 712.47 million in 2022 and is projected to hit around USD 5880.81 million by 2032, growing at a CAGR of 23.5% during the forecast period 2023 to 2032.

Some of the prominent players in the U.S. Molecular Diagnostics Market include:

• Abbott
• Siemens Healthcare GmbH
• QIAGEN
• F. Hoffmann-La Roche Ltd
• Quest Diagnostics Incorporated
• Danaher
• Thermo Fisher Scientific, Inc.
• Hologic Inc.
• BD
• Charles River Laboratories
• Bio-Rad Laboratories, Inc.
• Illumina, Inc.
• Agilent Technologies, Inc.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2020 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Molecular Diagnostics market.

By Disease 

• Healthcare-associated Infections (HAI)
  • Methicillin-resistant Staphylococcus Aureus
  • Staphylococcus Aureus
  • Enterovirus
  • Clostridioides Difficile
  • Van A
  • Sepsis Panel
• Respiratory
  • Flu
  • Respiratory Syncytial Virus
  • Paraflu
  • Multidrug-resistant Tuberculosis
  • Mycobacterium Avium-intracellulare
  • Group A Streptococcal
  • Adenovirus
  • Human Metapneumovirus
  • Rhinoviruses
  • Middle East Respiratory Syndrome Coronavirus
  • Tuberculosis
  • Severe Acute Respiratory Syndrome Coronavirus 2
  • Human Bocavirus-Infection
  • Bordetella
  • Mycoplasma Pneumonia
  • Respiratory Panels
• Gastrointestinal (GI)
  • Norovirus
  • Helicobacter Pylori
  • Shiga Toxin
  • GI Parasite Panel
  • GI Bacterial Panel
  • GI Viral Panel
  • GI Panels
• Women’s Health/STI
  • Chlamydia trachomatis (CT)/Neisseria Gonorrhoeae (NG)
  • Trichomonas Vaginalis
  • Mycoplasma Genitalium
  • Human Papillomavirus
  • Bacterial Vaginosis
  • Gonorrhoea Colloquially
  • Mycoplasma Genitalium Resistance
  • Herpes Simplex Virus
  • Group B Streptococcus
• Immunocompromised
  • Cytomegalovirus
  • Epstein-barr Virus
  • Varicella-zoster Virus
  • BK virus
• Virology
  • Human Immunodeficiency Viruses
  • Hepatitis C Virus
  • Hepatitis B Virus
  • Hepatitis E Virus
• Other Targets
  • Babesia
  • Zika
  • West Nile Virus
  • Chikungunya Virus/dengue Virus
  • Enhancer of Zeste Homolog 2
  • PIK3CA
  • Malaria
  • Monkeypox Virus
• Other Panels
  • Meningitis Panel
  • Lyme Panel
  • UTI Panel
• Oncology
  • Microsatellite Instability
  • B-raf
  • Epidermal Growth Factor Receptor
  • Kirsten RAT SARCOMA VIRUS
  • Others

By End-use 

• Hospital Core Laboratory
• Hospital Alternative Sites
• Decentralized Test Sites
• Reference Lab

Immediate Delivery Available | Buy This Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/8383

Unlocking Market Insights through Data Excellence

 The "Precedence Statistics" flexible dashboard is a powerful tool that offers real-time news updates, economic and market forecasts, and customizable reports. It can be configured to support a wide range of analysis styles and strategic planning needs. This tool empowers users to stay informed and make data-driven decisions in various scenarios, making it a valuable asset for businesses and professionals looking to stay ahead in today's dynamic and data-driven world.

 Access our Premium Real Time Data Intelligence Tool, Visit: www.precedencestatistics.com

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

About US

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

Connect with US

• Apt 1408 1785 RiversideDrive Ottawa, ON, K1G 3T7, Canada
• 2nd Floor, Shreeleela Plaza, Baner Road,Pune, Maharashtra - 411045
• USA - +1 9197 992 333 IND - +91 93077 85324
• sales@novaoneadvisor.com

Web: https://www.novaoneadvisor.com/

Blog: https://www.precedenceresearch.com/

Blog: https://www.towardshealthcare.com

Blog: https://www.towardspackaging.com

Blog:  https://www.visionresearchreports.com/